AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:55:00Z
New PBM Legislation Sparks Healthcare Selloff on Wall Street
Wed 11 Dec 24, 10:35 PMLawmakers Plot to Force Health Insurers to Sell Off Pharmacies
Wed 11 Dec 24, 01:00 PMGlenview, Sachem Head, Third Point buy CVS shares during Q3-filings
Fri 15 Nov 24, 12:05 AMLarry Robbins' Strategic Acquisition in Foley Trasimene Acquisition Corp
Mon 21 Oct 24, 03:01 PMAnalysis-Can the new CVS CEO handle the Aetna challenge?
Mon 21 Oct 24, 10:03 AMAre CVS Health Corporation's (NYSE:CVS) Mixed Financials Driving The Negative Sentiment?
Sun 20 Oct 24, 12:00 PMEvents leading up to CVS Health CEO Lynch's departure
Fri 18 Oct 24, 03:28 PMCVS replaces its CEO — and the stock drops 7%
Fri 18 Oct 24, 01:55 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 5628.00M | 10420.00M | 9770.00M | 8997.00M | 1406.00M |
| Minority interest | 16.00M | -12.00000M | 13.00M | -3.00000M | -2.00000M |
| Net income | 4311.00M | 7910.00M | 7179.00M | 6634.00M | -594.00000M |
| Selling general administrative | 745.00M | 36934.00M | 35072.00M | 33061.00M | 21368.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 54294.00M | 52048.00M | 49046.00M | 45528.00M | 31538.00M |
| Reconciled depreciation | 4247.00M | 4512.00M | 4441.00M | 4371.00M | 2718.00M |
| Ebit | 16251.00M | 13193.00M | 13911.00M | 11987.00M | 10174.00M |
| Ebitda | 20498.00M | 19676.00M | 18558.00M | 16482.00M | 12892.00M |
| Depreciation and amortization | 4247.00M | 6483.00M | 4647.00M | 4495.00M | 2718.00M |
| Non operating income net other | 169.00M | -270.00000M | -1234.00000M | 45.00M | 4.00M |
| Operating income | 16251.00M | 13193.00M | 13911.00M | 11987.00M | 4021.00M |
| Other operating expenses | 306385.00M | 277129.00M | 254795.00M | 244789.00M | 184409.00M |
| Interest expense | 2287.00M | 2503.00M | 2907.00M | 3035.00M | 2619.00M |
| Tax provision | 1463.00M | 2522.00M | 2569.00M | 2366.00M | 2002.00M |
| Interest income | 2287.00M | 2503.00M | 2907.00M | 3035.00M | 2619.00M |
| Net interest income | -2287.00000M | -2503.00000M | -2907.00000M | -3035.00000M | -2619.00000M |
| Extraordinary items | 0.00000M | 0.00000M | -9.00000M | 0.00000M | 100.00M |
| Non recurring | 8336.00M | 431.00M | - | - | 6149.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 1463.00M | 2522.00M | 2569.00M | 2366.00M | 2002.00M |
| Total revenue | 322467.00M | 292111.00M | 268706.00M | 256776.00M | 194579.00M |
| Total operating expenses | 38212.00M | 37066.00M | 35135.00M | 33541.00M | 21368.00M |
| Cost of revenue | 268173.00M | 240063.00M | 219660.00M | 211248.00M | 163041.00M |
| Total other income expense net | -10623.00000M | -2773.00000M | -4141.00000M | -2990.00000M | -6145.00000M |
| Discontinued operations | - | - | -9.00000M | -9.00000M | -9.00000M |
| Net income from continuing ops | 4165.00M | 7898.00M | 7201.00M | 6631.00M | -596.00000M |
| Net income applicable to common shares | 4149.00M | 7910.00M | 7179.00M | 6634.00M | -594.00000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 228275.00M | 232999.00M | 230715.00M | 222449.00M | 196456.00M |
| Intangible assets | 24754.00M | 29026.00M | 31142.00M | 33121.00M | 36524.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2685.00M | 5292.00M | 5277.00M | 5113.00M | 4581.00M |
| Total liab | 156960.00M | 157618.00M | 161014.00M | 158279.00M | 137913.00M |
| Total stockholder equity | 71015.00M | 75075.00M | 69389.00M | 63864.00M | 58225.00M |
| Deferred long term liab | 3880.00M | 6270.00M | 6794.00M | 7294.00M | 7677.00M |
| Other current liab | 47562.00M | 5604.00M | 5827.00M | 4821.00M | 4876.00M |
| Common stock | 48193.00M | 47377.00M | 46513.00M | 45972.00M | 45440.00M |
| Capital stock | 48193.00M | 47377.00M | 46513.00M | 45972.00M | 45440.00M |
| Retained earnings | 56145.00M | 54906.00M | 49640.00M | 45108.00M | 40911.00M |
| Other liab | 19948.00M | 19663.00M | 21033.00M | 21351.00M | 22460.00M |
| Good will | 78150.00M | 79121.00M | 79552.00M | 79749.00M | 78678.00M |
| Other assets | 7604.00M | 9801.00M | 51046.00M | 9059.00M | 8930.00M |
| Cash | 12945.00M | 9408.00M | 7854.00M | 5683.00M | 4059.00M |
| Cash and equivalents | 12945.00M | 9408.00M | 7854.00M | 5683.00M | 4059.00M |
| Total current liabilities | 69736.00M | 67807.00M | 62017.00M | 53303.00M | 44009.00M |
| Current deferred revenue | 3880.00M | 43808.00M | 37974.00M | 32613.00M | 28223.00M |
| Net debt | 57787.00M | 66591.00M | 77188.00M | 83319.00M | 69370.00M |
| Short term debt | 3456.00M | 5851.00M | 7078.00M | 5377.00M | 1985.00M |
| Short long term debt | 1778.00M | 4205.00M | 5440.00M | 3781.00M | 1985.00M |
| Short long term debt total | 70732.00M | 75999.00M | 85042.00M | 89002.00M | 73429.00M |
| Other stockholder equity | -31858.00000M | -28173.00000M | -28178.00000M | -28235.00000M | -28228.00000M |
| Property plant equipment | 12873.00M | 12896.00M | 12606.00M | 32904.00M | 11349.00M |
| Total current assets | 65682.00M | 60008.00M | 56369.00M | 50302.00M | 45243.00M |
| Long term investments | 21096.00M | 23025.00M | 20812.00M | 17314.00M | 15732.00M |
| Net tangible assets | 71015.00M | -33072.00000M | -41305.00000M | -49006.00000M | -56977.00000M |
| Short term investments | 2778.00M | 3117.00M | 3000.00M | 2373.00M | 2522.00M |
| Net receivables | 27276.00M | 24431.00M | 21742.00M | 19617.00M | 17631.00M |
| Long term debt | 50476.00M | 51971.00M | 59207.00M | 64699.00M | 71444.00M |
| Inventory | 19090.00M | 17760.00M | 18496.00M | 17516.00M | 16450.00M |
| Accounts payable | 14838.00M | 12544.00M | 11138.00M | 10492.00M | 8925.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 300.00M | 306.00M | 312.00M | 306.00M | 318.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1465.00000M | 965.00M | 1414.00M | 1019.00M | 102.00M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 48193.00M | 47377.00M | 46513.00M | 45972.00M | 45440.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 56145.00M | 54906.00M | 49640.00M | 45108.00M | 40911.00M |
| Treasury stock | -31858.00000M | -28173.00000M | -28178.00000M | -28235.00000M | -28228.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3968.00M | 4714.00M | 4624.00M | 4600.00M | 5046.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 162593.00M | 172991.00M | 174346.00M | 172147.00M | 151213.00M |
| Capital lease obligations | 18478.00M | 19823.00M | 20395.00M | 20522.00M | - |
| Long term debt total | 50476.00M | 51971.00M | 59207.00M | 64699.00M | 71444.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1017.00000M | -2717.00000M | -3172.00000M | -485.00000M | 125.00M |
| Change to liabilities | 4260.00M | 5919.00M | 5278.00M | 3550.00M | 2183.00M |
| Total cashflows from investing activities | -5047.00000M | -5261.00000M | -5534.00000M | -3339.00000M | -43285.00000M |
| Net borrowings | -4211.00000M | -9267.00000M | -5673.00000M | -5320.00000M | 38265.00M |
| Total cash from financing activities | -10516.00000M | -11356.00000M | -8155.00000M | -7850.00000M | 36819.00M |
| Change to operating activities | 7149.00M | 3018.00M | 2873.00M | 1182.00M | -149.00000M |
| Net income | 4165.00M | 7898.00M | 7192.00M | 6631.00M | -596.00000M |
| Change in cash | 614.00M | 1648.00M | 2176.00M | 1659.00M | 2395.00M |
| Begin period cash flow | 12691.00M | 11043.00M | 5954.00M | 4295.00M | 1900.00M |
| End period cash flow | 13305.00M | 12691.00M | 8130.00M | 5954.00M | 4295.00M |
| Total cash from operating activities | 16177.00M | 18265.00M | 15865.00M | 12848.00M | 8865.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 4247.00M | 4512.00M | 4441.00M | 4371.00M | 2718.00M |
| Other cashflows from investing activities | -1303.00000M | -24.00000M | 75.00M | -397.00000M | -41373.00000M |
| Dividends paid | 2907.00M | 2625.00M | 2624.00M | 2603.00M | 2038.00M |
| Change to inventory | -1435.00000M | 735.00M | -973.00000M | -1075.00000M | -1153.00000M |
| Change to account receivables | -2971.00000M | -2703.00000M | -1510.00000M | -2158.00000M | -1139.00000M |
| Sale purchase of stock | -3500.00000M | 549.00M | 257.00M | 185.00M | 688.00M |
| Other cashflows from financing activities | -449.00000M | 1523.00M | 10100.00M | 3809.00M | 44935.00M |
| Change to netincome | 2533.00M | 549.00M | 1073.00M | 453.00M | 6855.00M |
| Capital expenditures | 2727.00M | 2520.00M | 2437.00M | 2457.00M | 2037.00M |
| Change receivables | 2971.00M | -2703.00000M | -1510.00000M | 2158.00M | -1139.00000M |
| Cash flows other operating | 16177.00M | 1355.00M | 364.00M | 12848.00M | -3.00000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 614.00M | 1648.00M | 2176.00M | 1659.00M | 2399.00M |
| Change in working capital | 7003.00M | 3948.00M | 3159.00M | 1499.00M | -112.00000M |
| Stock based compensation | 447.00M | 484.00M | 400.00M | 453.00M | 280.00M |
| Other non cash items | 2390.00M | 1851.00M | 1243.00M | 548.00M | 6488.00M |
| Free cash flow | 13450.00M | 15745.00M | 13428.00M | 10391.00M | 6828.00M |
Sector: Healthcare Industry: Healthcare Plans
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CVS CVS Health Corp |
-0.82 1.81% | 44.46 | 12.06 | 9.08 | 0.29 | 1.34 | 0.47 | 8.96 |
| UNH UnitedHealth Group Incorporated |
-5.93 1.19% | 493.79 | 22.57 | 18.38 | 1.33 | 5.65 | 1.38 | 13.97 |
| ELV Elevance Health Inc |
1.20 0.33% | 367.46 | 18.00 | 12.66 | 0.65 | 2.87 | 0.74 | |
| CI Cigna Corp |
-4.215 1.49% | 278.19 | 30.25 | 10.09 | 0.39 | 2.10 | 0.50 | |
| HUM Humana Inc |
-5.62 2.34% | 234.23 | 19.16 | 14.60 | 0.56 | 3.37 | 0.53 |
CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.
One CVS Drive, Woonsocket, RI, United States, 02895
| Name | Title | Year Born |
|---|---|---|
| Ms. Karen Sue Lynch | Pres, CEO & Director | 1963 |
| Mr. Shawn Michael Guertin | Exec. VP & CFO | 1964 |
| Dr. Alan M. Lotvin M.D. | Exec. VP & Pres of Pharmacy Services | 1962 |
| Mr. James David Clark | Sr. VP, Controller & Chief Accounting Officer | 1965 |
| Mr. Tilak Mandadi | Exec. VP & Chief Data, Digital and Technology Officer | 1964 |
| Mr. Larry McGrath | Sr. VP of Bus. Devel. & Investor Relations | NA |
| Mr. Thomas Michael Moriarty | Exec. VP, Chief Policy & External Affairs Officer and Gen. Counsel | 1964 |
| Mr. David A. Falkowski | Exec. VP & Chief Compliance Officer | NA |
| Mr. Norman de Greve | Chief Marketing Officer | NA |
| Ms. Laurie P. Havanec | Exec. VP & Chief People Officer | 1961 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...